Here is the design of a clinical trial:

Official Title: Intravenous rhTNK-tPA Bridging With Endovascular Treatment Versus Endovascular Treatment Alone For Stroke Patient With Large Vessel Occlusion: A Multicenter, Randomized Controlled Trial

Included conditions:
- Stroke, Acute
- Stroke, Ischemic

Study Armgroups:
- {'label': 'Conbined treatment group', 'type': 'EXPERIMENTAL', 'description': 'intravenous tenecteplase bridging with endovascular treatment', 'interventionNames': ['Drug: rhTNK-tPA', 'Other: Endovascular treatment']}
- {'label': 'Endovascular treatment alone group', 'type': 'ACTIVE_COMPARATOR', 'description': 'endovascular treatment alone', 'interventionNames': ['Other: Endovascular treatment']}

Interventions:
- {'type': 'DRUG', 'name': 'rhTNK-tPA', 'description': 'intravenous thrombolysis with rhTNK-tPA followed by endovascular treatment', 'armGroupLabels': ['Conbined treatment group'], 'otherNames': ['TNKase', 'TNK-tPA']}
- {'type': 'OTHER', 'name': 'Endovascular treatment', 'description': 'endovascular treatment', 'armGroupLabels': ['Conbined treatment group', 'Endovascular treatment alone group'], 'otherNames': ['intra-arterial treatment', 'interventional therapy']}

Primary Outcomes:
- {'measure': 'Proportion of patients functionally independent (mRS score 0 to 2) at 90 days', 'description': 'functional independence', 'timeFrame': '90 days'}

Please estimate the sample size based on the assumption: 
80% power at a 2-sided α=0.05 significance level, with an attrition rate of 15% for protocol violations, treatment failure, and loss to follow-up.
Sample Size Estimates
        Based on 2 Chinese randomized controlled trials of direct mechanical thrombectomy for acute largeâvessel occlusive stroke,
3
, 
5
 it is assumed that the proportion of functional independence in the thrombectomyâalone group is 41%. Combining the results of 3 randomized controlled trials of intravenous tenecteplase followed by EVT in patients with stroke with LVO,
12
, 
16
, 
17
 we hypothesize that the proportion of functional independence in the tenecteplaseâplusâthrombectomy group will be 54%. Up to 462 (231 patients per arm) patients would provide 80% power at a 2âsided Î±=0.05 significance level. The sample size will be inflated to 544 (272 patients per arm) to account for a possible attrition rate of 15% for protocol violations, treatment failure, and loss to followâup. This calculation was conducted using PASS software version 15.0 (NCSS, LLC, Kaysville, UT).